In the RENEWAL trial, etanercept, a TNF alpha receptor inhibitor did not reduce the incidence of primary outcomes of mortality or hospitalization for HF (123), while in ATTACH (122), TNF Inhibitor infliximab actually caused an increased risk of hospitalization and mortality at high doses. This evidence concerns the gene TNF and hydrops fetalis.